Conni Bergmann Koury

Contributing Writer

  • All
  • Devices and Diagnostics
  • Pharma
Bausch + Lomb

August 31 2021

OSD Pipeline Update: Etiology-Specific Treatments for MGD, Demodex Getting Closer

First-in-class drugs are being investigated to treat two etiologies of dry eye disease (DED)—meibomian gland dysfunction (MGD) and Demodex blepharitis—both highly prevalent conditions for which ...
Read More

August 10 2021

NIH Awards Amydis $3 Million Grant Award for Novel Amyloid Beta Retinal Tracer Applicable to CNS Diseases

Amydis is developing novel small-molecule contrast agents that aim to enable the direct visualization of central nervous system (CNS) disease-related biomarkers in the retina. The ...
Read More

August 3 2021

Stem Cell-Engineered Implant for Geographic Atrophy Shows Promise, Long-Term Survival of Cells in Early Trial

A number of companies are developing drug treatments for geographic atrophy, the result of advanced dry age-related macular degeneration (AMD), for which no approved treatments ...
Read More

April 14 2021

Anterior Segment Advances That ‘Won’ 2020 and Those Poised To Disrupt the Future

2020 was a challenging year for ophthalmic surgeons, but an array of device and pharma developments helped them get through it, while other advances are ...
Read More

April 7 2021

With $36 Million, Visus Starts Phase II Trial of Presbyopia Drop Brimochol

In another sign of the intense interest in the category of presbyopia-correcting drops, Visus Therapeutics raised $36 million in Series A financing that will be ...
Read More

March 10 2021

Pioneering Ophthalmic Innovator Patricia Bath, MD, Nominated for National Inventors Hall of Fame

One might say the word trailblazer was invented to describe Patricia Era Bath, MD. In 1973 she was the first African-American to complete an ophthalmology ...
Read More

February 2 2021

Merge Ahead: Where the Parallel Tracks for Future Innovations in Presbyopia May Meet

Innovations for treating presbyopia are moving on two parallel tracks: accommodative intraocular lenses (IOLs) that are both reversable and exchangeable, and pharmaceutical drops to temporarily ...
Read More

January 26 2021

Heru Emerges from Stealth Mode to Leverage AI, VR to Test and Treat Visual Field Defects

Heru, an ophthalmology development company creating an artificial intelligence-driven vision diagnostics and augmentation platform, has just emerged from “stealth mode” and made its public debut ...
Read More

November 18 2020

Tarsus Closes IPO, Starts Phase IIb/III Trials for Demodex Blepharitis Drop

Late-stage biotech Tarsus Pharmaceuticals raised $88 million in its October NASDAQ debut. In announcing the close of its initial public offering, the company stated that ...
Read More

September 22 2020

Despite Tepid Wall Street Response, Outlook Therapeutics Still Betting on Ophthalmic Bevacizumab Formulation

As Outlook Therapeutics announced top-line results from the first of two registration clinical trials evaluating the safety and efficacy of its formulation of bevacizumab-vikg, ONS-5010, ...
Read More

August 5 2020

Osmotica Will Commercialize and Supply Non-Surgical Droopy Lid Treatment via a Wholly Owned Subsidiary

Last month, the US Food and Drug Administration approved a novel ophthalmic solution to treat acquired blepharoptosis, otherwise known as “droopy lid syndrome.” The solution, ...
Read More
With Positive Phase III Results, Oyster Point Pharma Banks $120 Million from Public Offering

July 1 2020

With Positive Phase III Results, Oyster Point Pharma Banks $120 Million from Public Offering

Oyster Point Pharma has taken two big steps recently to advance development of its OC-01 nasal-spray candidate to treat dry eye disease: the closing of ...
Read More